Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in mycosis fungoides
Innate Pharma announces its participation in upcoming investor conferences
Innate Pharma highlights abstracts selected for ASCO 2024 Annual Meeting
Outcome of Innate Pharma’s 2024 Annual General Meeting
Clarification regarding SAR443579 Designation
Innate Pharma highlights abstracts selected for EHA 2024 congress
Innate Pharma reports first quarter 2024 business update and financial results
Innate Pharma announces conference call and webcast for Q1 2024 business update
Innate Pharma announces advancement of Sanofi-developed NK Cell Engager SAR443579/IPH6101 progressing to Phase 2 for blood cancer patients
